Shareholder Class Action

Talecris Biotherapeutics Holdings Corp. is selling itself too cheaply to Grifols Inc., for $3.4 billion or a $19 share plus 0.641 shares of new, nonvoting Grifols stock for each Talecris share, shareholders claim in Delaware Chancery Court.

Exit mobile version